Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Teoxane S.A.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Teoxane S.A.

Regulatory records
10
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 10 FDA records to the applicant name Teoxane S.A.. 7 entries are PMA supplements. 3 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Sep 18, 2025 to Aug 31, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code LMH appears in 10 of the 10 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P170002, with 10 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: Les Charmilles Rue De Lyon, 105, Geneva, 1203. Recorded on P170002/S059, decision dated Aug 31, 2026.

Changes described in PMA records

P170002/S059: RHA 2, RHA 3, RHA 4

FDA’s recorded scope: Approval for an alternative qualified laboratory for Biological Indicator release testing as part of receiving inspection

Aug 31, 2026 · 30-Day Notice

P170002/S058: RHA 2, RHA 3, RHA 4

FDA’s recorded scope: Approval for the replacement of glass crystallizers with Stainless Steel 316L crystallizers

Aug 28, 2026 · 30-Day Notice

P170002/S055: RHA Kiss Volume

FDA’s recorded scope: approval for updating the labeling of RHA3 Mepi to a new commercial name, RHA Kiss Volume, that includes a smaller gauge (30G) needle in its packaging, color change to the syringe finger grip and plunger rod, and updated labeling including use of 27G or 30G needle when injecting for both approved indications, in the lips and nasolabial folds.

Jul 27, 2026 · Real-Time Process

P170002/S052: RHA Redensity, RHA Redensity Mepi

FDA’s recorded scope: Approval for the final labeling of RHA Redensity Mepi. This follows the completion of the post-approval study to investigate whether RHA Redensity Mepi (with mepivacaine) is non-inferior to RHA Redensity (with lidocaine) for injection site pain felt during injection in FST V/VI subjects.

Jul 2, 2026 · Normal 180 Day Track No User Fee

P170002/S050: RHA Redensity Eye Lido; RHA Redensity Eye

FDA’s recorded scope: Approval for RHA Redensity Eye Lido and RHA Redensity Eye for expanding the indications to include injection into the sub-dermis and supraperiosteum for the correction of moderate to severe tissue volume deficiencies in the infraorbital region in adults aged 22 years or older.

May 12, 2026 · Panel Track

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Devices & associated records

Product / regulatory recordCompanyPathwayDecision dateSource
Teoxane S.A.PMA supplementAug 31, 2026FDA
Teoxane S.A.PMA supplementAug 28, 2026FDA
RHA Kiss VolumeP170002/S055
Teoxane S.A.PMA supplementJul 27, 2026FDA
Teoxane S.A.PMA supplementJul 2, 2026FDA
Teoxane S.A.PMA supplementMay 12, 2026FDA
Teoxane S.A.PMA supplementApr 7, 2026FDA
Teoxane S.A.PMA supplementApr 1, 2026FDA
Teoxane S.A.PMA supplementMar 31, 2026FDA
Teoxane S.A.PMA supplementJan 14, 2026FDA
Teoxane S.A.PMA supplementSep 18, 2025FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 20, 2026.